Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Biswas, Nidhan K ^a   Chandra, Vikas ^a   Sarkar Roy, Neeta ^a   Das, Tapojyoti ^a   Bhattacharya, Rabindra N ^b   Tripathy, Laxmi N ^c   Basu, Sunandan K ^c   Kumar, Shantanu ^a   Das, Subrata ^a   Chatterjee, Ankita ^a   Mukherjee, Ankur ^a   Basu, Pryiadarshi ^a   Maitra, Arindam ^a   Chattopadhyay, Ansuman ^d   Basu, Analabha ^a   Dhara, Surajit ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL GENOMICS   (India)

^b AMRI HOSPITALS   (India)

^c Medica Superspeciality Hospital   (India)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILIDE; DACARBAZINE; PYRIDINE DERIVATIVE; SHH PROTEIN, HUMAN; SONIC HEDGEHOG PROTEIN; TEMOZOLOMIDE; TUMOR PROTEIN; VISMODEGIB;

ALLELE; ANALOGS AND DERIVATIVES; CELL CYCLE G2 PHASE; CELL DIVISION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG EFFECTS; EXOME; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETICS; GLIOBLASTOMA; HUMAN; MALE; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; RADIOGRAPHY; TUMOR CELL LINE;

ALLELES; ANILIDES; CELL DIVISION; CELL LINE, TUMOR; DACARBAZINE; EXOME; FEMALE; FOLLOW-UP STUDIES; G2 PHASE; GENE FREQUENCY; GLIOBLASTOMA; HEDGEHOG PROTEINS; HUMANS; MALE; NEOPLASM PROTEINS; PYRIDINES; RADIOGRAPHY; SPHEROIDS, CELLULAR;

EID: 84923100326     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07915     Document Type: Article

References (36)

1. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 352, 987-996 (2005).
2. Hoeijmakers, J. H. DNA damage, aging, and cancer. The New England journal of medicine 361, 1475-1485 (2009).
3. Denny, B. J., Wheelhouse, R. T., Stevens, M. F., Tsang, L. L.&Slack, J. A.NMRand molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry. 33, 9045-9051 (1994).
4. Roos, W. P.&Kaina, B. DNA damage-induced cell death by apoptosis. Trends in molecular medicine 12, 440-450 (2006).
5. Ciccia, A.&Elledge, S. J. The DNA damage response: making it safe to play with knives. Molecular cell. 40, 179-204 (2010).
6. Shipitsin, M. et al.Molecular definition of breast tumor heterogeneity. Cancer cell. 11, 259-273 (2007).
7. Brock, A., Chang, H.&Huang, S. Non-genetic heterogeneity-a mutationindependent driving force for the somatic evolution of tumours. Nat Rev Genet. 10, 336-342 (2009).
8. Marusyk, A., Almendro, V.&Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer? Nature reviews. 12, 323-334 (2012).
9. Almendro, V., Marusyk, A.&Polyak, K. Cellular heterogeneity and molecular evolution in cancer. Annual review of pathology. 8, 277-302 (2013).
10. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (New York, N.Y. 344, 1396-1401 (2014).
11. Newlands, E. S. et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). British journal of cancer. 65, 287-291 (1992).
12. Shackleton, M., Quintana, E., Fearon, E. R.&Morrison, S. J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 138, 822-829 (2009).
13. Aparicio, S.&Caldas, C. The implications of clonal genome evolution for cancer medicine. The New England journal of medicine. 368, 842-851 (2013).
14. Mihaliak, A. M. et al. Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. Cancer letters. 296, 168-177 (2010).
15. Amakye, D., Jagani, Z.&Dorsch, M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nature medicine. 19, 1410-1422 (2013).
16. Axelson, M. et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 19, 2289-2293 (2013).
17. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell. 155, 462-477 (2013).
18. Chitikova, Z. V. et al. Sustained activation of DNA damage response in irradiated apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers. Cell cycle (Georgetown, Tex. 13, 1424-1439 (2014).
19. Hubbs, A. E.,Majidi, M. &Lichy, J. H. Expression of an isoform of the novel signal transduction protein ST5 is linked to cell morphology. Oncogene. 18, 2519-2525 (1999).
20. Roukos, V. et al. Spatial dynamics of chromosome translocations in living cells. Science (New York, N.Y. 341, 660-664 (2013).
21. Novotna, E. et al. DNA-dependent protein kinase and its inhibition in support of radiotherapy. International journal of radiation biology. 89, 416-423 (2013).
22. Houslay, M. D. A RSK(y) relationship with promiscuous PKA. Sci STKE. 2006, pe32 (2006).
23. Timmer, J. R., Mak, T. W., Manova, K., Anderson, K. V.&Niswander, L. Tissue morphogenesis and vascular stability require the Frem2 protein, product of the mouse myelencephalic blebs gene. Proceedings of the National Academy of Sciences of the United States of America. 102, 11746-11750 (2005).
24. Murone, M. et al. Gli regulation by the opposing activities of fused and suppressor of fused. Nature cell biology. 2, 310-312 (2000).
25. Wilson, C. W. et al. Fused has evolved divergent roles in vertebrate Hedgehog signalling and motile ciliogenesis. Nature. 459, 98-102 (2009).
26. Struys, E. A.&Jakobs, C. Metabolism of lysine in alpha-aminoadipic semialdehyde dehydrogenase-deficient fibroblasts: evidence for an alternative pathway of pipecolic acid formation. FEBS letters. 584, 181-186 (2010).
27. Feldmann, G. et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer research. 67, 2187-2196 (2007).
28. Karhadkar, S. S. et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 431, 707-712 (2004).
29. Turner, N. C. et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. The EMBO journal. 27, 1368-1377 (2008).
30. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine. 352, 997-1003 (2005).
31. Butowski, N. et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro-oncology. 13, 1331-1338 (2011).
32. Zahreddine, H. A. et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 511, 90-93 (2014).
33. Gruber Filbin, M. et al. Coordinate activation of Shh and PI3K signaling in PTENdeficient glioblastoma: new therapeutic opportunities. Nature medicine. 19, 1518-1523 (2013).
34. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic acids research. 29, e45 (2001).
35. Maitra, A. et al. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nature communications. 4, 2873 (2013).
36. Benjamini, Y. H. Yosef Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. 57, 289-300 (1995).